Pakistan’s Ambassador to Egypt Sajid Bilal visited on Sunday the Integrated Diagnostics Holdings (IDH) headquarters to look into relations between IDH and Pakistani companies.
The visit came just weeks after IDH signed a sales and purchase agreement to acquire Evercare Group’s 50 per cent stake in Islamabad Diagnostic Centre (IDC), one of Pakistan’s largest, most respected, and fastest growing integrated diagnostics companies.
The IDH, a leading consumer healthcare company with operations in Egypt, Jordan, Sudan, and Nigeria, welcomed a visit by the Pakistani envoy.
They discussed enhancing cooperation between IDH and Pakistani companies as well as investment opportunities in Pakistan’s healthcare sector.
The visit comes as part of Pakistan’s wider strategy to consolidate its relations with Egypt, especially in infrastructure projects, health, training, and joint investments.
During the meeting, IDH’s officials discussed specific investment opportunities within the fast-growing Pakistani healthcare sector, with Ambassador Sajid Bilal stressing the strategic importance of attracting leading Egyptian healthcare companies like IDH to the sector.
During the visit, Ambassador Bilal pointed out that IDC enjoys a strong reputation amongst both patients and regulatory authorities in Pakistan, and is widely considered as one of the leading diagnostics providers in the country.
He also mentioned that IDH’s decision to invest in Pakistan is testament to the attractiveness of the country’s investment policies and to the company’s trust in the government’s future vision.
Commenting on the visit, IDH CEO Hend El Sherbini, said: “We are very pleased to welcome the Pakistani ambassador to discuss future opportunities of co-operation in Pakistan.
The country’s healthcare market represents an appealing investment opportunity for IDH due to its robust fundamentals. The Pakistani diagnostics industry shares many of the similar characteristics as our current markets of operation making it an ideal location for our platform to deliver exceptional quality of care to a broad and growing patient-base.
We expect to close our first transaction in the market during the first half of 2022, and I look forward to visiting Pakistan in the near future.”
